Compare PHIN & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHIN | NRIX |
|---|---|---|
| Founded | 2023 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2023 | 2020 |
| Metric | PHIN | NRIX |
|---|---|---|
| Price | $57.16 | $25.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $91.60 | $34.50 |
| AVG Volume (30 Days) | 381.2K | ★ 1.7M |
| Earning Date | 10-29-2026 | 10-12-2026 |
| Dividend Yield | ★ 2.07% | N/A |
| EPS Growth | ★ 84.09 | N/A |
| EPS | 2.01 | ★ 3.26 |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | $4.59 | $786.93 |
| Revenue Next Year | $3.61 | N/A |
| P/E Ratio | $28.74 | ★ $7.51 |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $51.28 | $10.15 |
| 52 Week High | $86.94 | $28.23 |
| Indicator | PHIN | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 34.39 | 58.82 |
| Support Level | N/A | $24.61 |
| Resistance Level | $81.54 | $28.23 |
| Average True Range (ATR) | 1.49 | 1.11 |
| MACD | 0.21 | 0.31 |
| Stochastic Oscillator | 32.38 | 92.61 |
Phinia Inc is engaged in the development, design, and manufacture of integrated components and systems that optimize performance, increase efficiency, and reduce emissions in combustion and hybrid propulsion for commercial vehicles, industrial applications, and light vehicles. Its product portfolio includes alternative fuel systems, fuel delivery modules, evaporative canisters, diesel fuel injection systems, electrical systems, hydrogen solutions, associated software, and others. The company's reportable segments are; the Fuel Systems segment, which derives key revenue, and the Aftermarket segment. Geographically, it generates maximum revenue from the United States and the rest from the United Kingdom, China, Poland, Romania, Brazil, and other regions.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.